Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2026

The poly adp-ribose polymerase (parp) inhibitor market size has grown rapidly in recent years. It will grow from $9.28 billion in 2025 to $10.32 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, advancements in dna repair pathway research, regulatory approvals for first-generation parp inhibitors, growing adoption of targeted cancer therapies, expansion of oncology clinical research.

The poly adp-ribose polymerase (parp) inhibitor market size is expected to see strong growth in the next few years. It will grow to $14.93 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing focus on precision oncology, rising development of next-generation parp inhibitors, expanding indications beyond ovarian and breast cancer, growing investment in oncology drug pipelines, increased use of companion diagnostics. Major trends in the forecast period include expanding use of parp inhibitors in combination therapies, growing focus on brca-mutated cancer treatments, increasing clinical trials for new parp molecules, rising adoption of personalized oncology treatments, enhanced patient stratification using biomarkers.

The growing prevalence of ovarian cancer is expected to drive the growth of the poly ADP-ribose polymerase (PARP) inhibitor market going forward. Ovarian cancer is a malignant tumor that forms in one or both ovaries, which are part of the female reproductive system responsible for producing eggs and female hormones. The incidence of ovarian cancer is increasing due to factors such as genetic predisposition, an aging population, environmental exposure, and hormonal imbalances. PARP inhibitors are used in ovarian cancer treatment to target DNA repair pathways, particularly in patients with BRCA mutations, resulting in synthetic lethality and increased tumor cell death. For instance, in February 2024, according to the World Ovarian Cancer Coalition, a Canada-based nonprofit organization, the annual number of deaths from ovarian cancer is projected to reach 350,956, representing an increase of nearly 70% compared to 2022. Therefore, the rising prevalence of ovarian cancer is contributing to the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.

Major companies operating in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on developing generic PARP inhibitors to provide more tailored treatment options for cancer patients with specific genetic mutations. Generic PARP inhibitors are drugs that inhibit the activity of the poly ADP-ribose polymerase enzyme involved in DNA repair. For instance, in March 2024, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib under the IBYRA brand to improve access to advanced cancer therapies. IBYRA targets genetic mutations associated with breast, ovarian, prostate, and pancreatic cancers, offering a personalized and effective treatment option. The drug is especially beneficial for patients with HRD-positive or BRCA mutations, helping to slow disease progression.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. Through this acquisition, Ariceum Therapeutics expanded its radiopharmaceutical portfolio by gaining access to innovative radiolabeled PARP inhibitor therapies. Theragnostics Ltd. is a UK-based biotechnology company focused on developing radiolabeled PARP inhibitors for tumor diagnosis and treatment.

Major companies operating in the poly adp-ribose polymerase (parp) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Ipsen Biopharmaceuticals Inc., Genentech Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc.

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly adp-ribose polymerase (parp) inhibitor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the poly adp-ribose polymerase (parp) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the poly ADP-ribose polymerase inhibitor market by increasing costs of imported active pharmaceutical ingredients, specialized reagents, clinical trial materials, and manufacturing equipment used in oncology drug production. Pharmaceutical companies in North America and Europe are most affected due to reliance on global API sourcing, while Asia-Pacific faces cost pressures in contract manufacturing and export-oriented drug production. These tariffs are raising development and production costs and may influence drug pricing strategies. However, they are also encouraging localized API manufacturing, regional supply chain diversification, and increased investment in domestic oncology drug production capabilities.

The poly adp-ribose polymerase (parp) inhibitor market research report is one of a series of new reports that provides poly adp-ribose polymerase (parp) inhibitor market statistics, including poly adp-ribose polymerase (parp) inhibitor industry global market size, regional shares, competitors with a poly adp-ribose polymerase (parp) inhibitor market share, detailed poly adp-ribose polymerase (parp) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the poly adp-ribose polymerase (parp) inhibitor industry. This poly adp-ribose polymerase (parp) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Poly ADP ribose polymerase (PARP) inhibitors are a group of pharmacological agents that inhibit the PARP enzyme, which plays a key role in deoxyribonucleic acid (DNA) repair. By blocking this enzyme, these inhibitors are effective in treating cancers that already have defects in other DNA repair mechanisms, as they prevent cancer cells from repairing damaged DNA, ultimately leading to cell death.

The main drug types of poly ADP ribose polymerase (PARP) inhibitors include talazoparib, veliparib, olaparib, and others. Talazoparib is a highly potent PARP inhibitor used in cancer treatment by interfering with DNA repair processes within cancer cells. These drugs are distributed through channels such as hospital pharmacies, online pharmacies, retail pharmacies, and others. They are used for indications including ovarian cancer, breast cancer, and other cancers, and are utilized by end users such as hospitals, homecare settings, specialty clinics, and others.

The poly ADP-ribose polymerase (PARP) inhibitor market consists of revenues earned by entities by providing services such as diagnostic tests, clinical trials, consulting services, and patient support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The poly ADP-ribose polymerase (PARP) inhibitor market also includes sales of test kits, laboratory equipment, imaging systems, sample processing instruments, reagents, and chemicals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.